# Trevena CEO to Present at the 2015 Wedbush PacGrow Healthcare Conference 

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that Maxine Gowen, Ph.D., chief executive officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. EDT in New York.

To access the live audio webcast of the presentation, please visit the "Investors" section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.


#### Abstract

About Trevena Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

View source version on businesswire.com: http://www.businesswire.com/news/home/20150804005494/en/

\section*{Investor Contacts:}

Trevena, Inc. Jonathan Violin Director of investor relations 610-354-8840 x231 jviolin@trevenainc.com or Argot Partners Andrea Rabney President and chief executive officer 212-600-1902 andrea@argotpartners.com or Media Contact: Argot Partners Eliza Schleifstein 917-763-8106 eliza@argotpartners.com


Source: Trevena, Inc.

